Get the Daily Brief
Latest Biotech News
AI in drug discovery and enterprise execution
Bristol Myers Squibb moved its AI program beyond chatbots, announcing a partnership with Anthropic to deploy Claude across its global operations. BMS said it will embed the system across research,...
Precision oncology diagnostics: broader liquid CDx footprint gets FDA approval
Guardant Health secured FDA approval for its upgraded Guardant360 Liquid CDx, expanding the test’s clinical utility with a reported 100-fold larger genomic footprint compared with the prior...
Lung cancer: ADC plus Keytruda posts randomized Phase 3 progression advantage
Merck and Kelun-Biotech reported a Phase 3 readout showing sacituzumab tirumotecan (sac-TMT) combined with Keytruda cut the risk of disease progression or death by 65% versus Keytruda alone in...
Parkinson’s genetics: LRRK2 therapy fails to slow disease in randomized trial
Biogen and Denali Therapeutics said their investigational Parkinson’s therapy targeting LRRK2 failed in a randomized trial to slow neurodegeneration. The study randomized 648 adults with...
Gene therapy safety: trial closure after patient death leaves mechanism unresolved
Capsida Biotherapeutics confirmed it closed its SYNRGY Phase I/II gene therapy trial for STXBP1-related DEE after the previously reported death of a child who received CAP-002. The company cited...
Company dealmaking: Lilly expands genetics pipeline via DNA delivery acquisition
Eli Lilly agreed to buy Engage Bio, a preclinical-stage startup developing non-viral DNA delivery technology, as the company continues expanding in genetic medicines. The deal includes $202...
Cardiovascular interventions: Cagent raises $41M to expand coronary IVL platform
Cagent Vascular closed an oversubscribed $41 million Series D to advance its dual-modality intravascular lithotripsy platform toward coronary commercialization and further clinical testing. The...
Biotech M&A: Liminatus to buy InnocsAI for $320M stock for next-gen CAR-T pipeline
Liminatus Pharma agreed to acquire CAR-T biotech InnocsAI in a stock deal valued at $320 million, gaining access to an oncology pipeline centered on bivalent CD19xCD22 CAR-T. InnocsAI’s lead asset...
GLP-1 supply-chain compliance under FDA import restrictions
The FDA issued a warning letter to Harbin Jixianglong Biotech after inspections found the company allegedly attempted to bypass recently introduced GLP-1 receptor agonist import safeguards for...
First randomized phase 3 win for an ADC–PD-1 frontline lung cancer combo
Merck and Kelun-Biotech reported Phase 3 results for sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (Keytruda) in treatment-naïve, PD-L1–positive non-small cell lung cancer, showing a 65%...
Checkpoint diagnostics expand: Guardant360 Liquid CDx gets FDA approval
Guardant Health received FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to support treatment selection in advanced cancer. The company said...
Targeted oncology diagnostics: FoundationOne CDx approved for Tepmetko across tissue and liquid
FDA approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic for EMD Serono’s Tepmetko (tepotinib) to identify metastatic NSCLC patients with MET exon 14 skipping alterations....
Clinical failure: LRRK2-targeting Parkinson’s pill does not slow disease
Biogen and Denali Therapeutics said their experimental Parkinson’s therapy targeting LRRK2 failed to slow disease progression in a randomized trial. The study randomized 648 adults with...
AI platforms move from pilots to enterprise integration in Big Pharma
Bristol Myers Squibb announced a partnership with Anthropic to deploy Claude across its global operations, with plans to integrate the system across research, clinical development, manufacturing,...
AI-enabled protein design targets GPCR conformations
A study led by researchers at the University of Washington Institute for Protein Design and Skape Bio reported AI-driven de novo protein design of miniproteins that can switch GPCRs on or off with...
Obesity clinical pipeline: Lilly retatrutide Phase 3 top-line results and longer-term data direction
Eli Lilly reported top-line Phase 3 results for retatrutide in obesity, describing weight loss outcomes up to 28% at the highest tested doses over 80 weeks. The company also said the dataset shows...
Venture funding for inflammation and immunology: cAMPfield raises Series A
cAMPfield Therapeutics, a San Diego biotech working on inflammatory and immunology medicines, raised an $180 million Series A, according to the report. The company’s financing highlights continued...
Growth-stage company deal: InSphero acquires PhenoVista Biosciences for imaging and phenotypic assays
InSphero announced it has acquired PhenoVista Biosciences, a cell-based assay services provider specializing in high-content imaging and phenotypic assay technologies. The deal is expected to...
Frontline lung cancer efficacy readouts for ADC–immunotherapy combos
Merck and Kelun-Biotech reported Phase 3 results at ASCO 2026 showing that the TROP2-directed sacituzumab tirumotecan (sac-TMT) added to Keytruda cut the risk of disease progression or death by...
FDA expands companion diagnostic access for MET exon 14 NSCLC
The FDA approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic for EMD Serono’s Tepmetko (tepotinib) to identify metastatic NSCLC patients with MET exon 14 skipping...